Topics:

Merck chief doubles down on 'good cholesterol' drug

Tools

Even as failures in the field pile up, Merck ($MRK) CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or "good" cholesterol. And despite growing doubts about the prospects for such treatments, he appears to see the risky bet worth the potential payoff. Report

Filed Under